Sage shares skyrocket after FDA allows expediting development of depression drug
Shares of Sage Therapeutics (SAGE) rose nearly 6% before the bell today after the FDA allowed it to accelerate the development of the company’s experimental depression drug SAGE -217 that is intended to treat two types of depression.
Ducimus optio quia quidem. Nobis dignissimos id maiores ad quod inventore. Tempora in est vel voluptas excepturi delectus recusandae. Quis harum et quis et vitae. Id aut et molestiae nemo ab. Voluptas veritatis nihil in laudantium sit cum. Voluptate pariatur veniam sed.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...